- Phase I Dose-Escalation Study of Intravenous Aflibercept in Combination with Docetaxel in Patients with Advanced Solid Tumors
[作者:Isambert, N; Freyer, G; Zanetta, S; You, B; Fumoleau, P; Falandry, C; Favier, L; Assadourian, S; Soussan-Lazard, K; Ziti-Ljajic, S; Trillet-Lenoir, V,期刊:Clinical Cancer Research, 页码:1743-1750 , 文章类型: Article,,卷期:2012年18-6]
- Purpose: This phase I study cohort investigated aflibercept in combination with docetaxel in patients with advanced solid tumors. Materials and Methods: Eligible patients had metastatic or nonresectable cancer for which ...
- Randomized Study of Autologous Cytokine-Induced Killer Cell Immunotherapy in Metastatic Renal Carcinoma
[作者:Liu, L; Zhang, WH; Qi, XY; Li, H; Yu, JP; Wei, S; Hao, XS; Ren, XB,期刊:Clinical Cancer Research, 页码:1751-1759 , 文章类型: Article,,卷期:2012年18-6]
- Purpose: The therapeutic benefit of the cytokine-induced killer (CIK) cells was unknown in the renal cell carcinoma (RCC). This prospectively randomized study was conducted to evaluate the effects of autologous CIK cell ...
- High EGFR Gene Copy Number and Skin Rash as Predictive Markers for EGFR Tyrosine Kinase Inhibitors in Patients with Advanced Squamous Cell Lung Carcinoma
[作者:Lee, Y; Shim, HS; Park, MS; Kim, JH; Ha, SJ; Kim, SH; Cho, BC,期刊:Clinical Cancer Research, 页码:1760-1768 , 文章类型: Article,,卷期:2012年18-6]
- Purpose: This study aimed to search for predictors of epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKI) efficacy in previously treated patients with advanced squamous cell lung carcinoma in which E...
- KRAS and BRAF Mutations Predict Primary Resistance to Imatinib in Gastrointestinal Stromal Tumors
[作者:Miranda, C; Nucifora, M; Molinari, F; Conca, E; Anania, MC; Bordoni, A; Saletti, P; Mazzucchelli, L; Pilotti, S; Pierotti, MA; Tamborini, E; Greco, A; Frattini, M,期刊:Clinical Cancer Research, 页码:1769-1776 , 文章类型: Article,,卷期:2012年18-6]
- Purpose: Gastrointestinal stromal tumors (GIST) are characterized by gain-of-function mutations in KIT/PDGFRA genes leading to a constitutive receptor activation which is well counteracted by imatinib. However, cases in ...
- PIK3CA/PTEN Mutations and Akt Activation As Markers of Sensitivity to Allosteric mTOR Inhibitors
[作者:Meric-Bernstam, F; Akcakanat, A; Chen, HQ; Do, KA; Sangai, T; Adkins, F; Gonzalez-Angulo, AM; Rashid, A; Crosby, K; Dong, M; Phan, AT; Wolff, RA; Gupta, S; Mills, GB; Yao, J,期刊:Clinical Cancer Research, 页码:1777-1789 , 文章类型: Article,,卷期:2012年18-6]
- Purpose: We sought to determine whether phosphoinositide 3-kinase (PI3K) pathway mutation or activation state and rapamycin-induced feedback loop activation of Akt is associated with rapamycin sensitivity or resistance. ...
- EGFR Exon 19 Insertions: A New Family of Sensitizing EGFR Mutations in Lung Adenocarcinoma
[作者:He, M; Capelletti, M; Nafa, K; Yun, CH; Arcila, ME; Miller, VA; Ginsberg, MS; Zhao, BS; Kris, MG; Eck, MJ; Janne, PA; Ladanyi, M; Oxnard, GR,期刊:Clinical Cancer Research, 页码:1790-1797 , 文章类型: Article,,卷期:2012年18-6]
- Purpose: Epidermal growth factor receptor (EGFR) genotyping is now standard in the management of advanced lung adenocarcinoma, as this biomarker predicts marked benefit from treatment with EGFR tyrosine kinase inhibitors...
|